{"acquisitions":[],"changes":[],"country":"FR","description":"STEP Pharma develops dencatistat (STP938), a first-in-class oral CTPS1 inhibitor designed to treat T-cell lymphomas, B-cell lymphomas, solid tumors, and essential thrombocythaemia. It targets oncology patients in cancers where survival has stagnated for decades, especially peripheral T-cell lymphoma. Most advanced selective CTPS1 inhibitor in clinical development.","domain":"step-ph.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":46.243244,"lng":6.020778,"location":"Saint-Genis-Pouilly, France","multiples":[],"name":"STEP Pharma","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2700000,"connectionsAmong":[],"currency":"EUR","date":"2026-04-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"step-ph-com-2026-04-01-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"step-ph-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"step-ph.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://step-ph.com"},{"fact":"description","publisher":"step-ph.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://step-ph.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Nginx","WordPress 7.0","Yoast SEO 27.6","Slider Revolution","jQuery Migrate 3.4.1","imagesLoaded 5.0.0","PHP","MySQL","jquery 3."],"totalRaisedUsd":2700000,"traction":[],"updatedAt":"2026-05-08","valuations":[]}